244 related articles for article (PubMed ID: 20020049)
1. Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice.
Nierkens S; den Brok MH; Roelofsen T; Wagenaars JA; Figdor CG; Ruers TJ; Adema GJ
PLoS One; 2009 Dec; 4(12):e8368. PubMed ID: 20020049
[TBL] [Abstract][Full Text] [Related]
2. Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells.
Nierkens S; den Brok MH; Garcia Z; Togher S; Wagenaars J; Wassink M; Boon L; Ruers TJ; Figdor CG; Schoenberger SP; Adema GJ; Janssen EM
Cancer Res; 2011 Oct; 71(20):6428-37. PubMed ID: 21788345
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity mediated by CpG: the route of administration is critical.
Lou Y; Liu C; Lizée G; Peng W; Xu C; Ye Y; Rabinovich BA; Hailemichael Y; Gelbard A; Zhou D; Overwijk WW; Hwu P
J Immunother; 2011 Apr; 34(3):279-88. PubMed ID: 21389870
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.
Karan D; Krieg AM; Lubaroff DM
Int J Cancer; 2007 Oct; 121(7):1520-8. PubMed ID: 17565748
[TBL] [Abstract][Full Text] [Related]
5. Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity.
Alteber Z; Azulay M; Cafri G; Vadai E; Tzehoval E; Eisenbach L
Cancer Immunol Immunother; 2014 Apr; 63(4):369-80. PubMed ID: 24452202
[TBL] [Abstract][Full Text] [Related]
6. Soluble β-glucan from Grifola frondosa induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity.
Masuda Y; Nawa D; Nakayama Y; Konishi M; Nanba H
J Leukoc Biol; 2015 Dec; 98(6):1015-25. PubMed ID: 26297795
[TBL] [Abstract][Full Text] [Related]
7.
Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
9. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
11. TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasis.
Xu A; Zhang L; Yuan J; Babikr F; Freywald A; Chibbar R; Moser M; Zhang W; Zhang B; Fu Z; Xiang J
Cell Mol Immunol; 2019 Oct; 16(10):820-832. PubMed ID: 30467420
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
13. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.
Jacobs C; Duewell P; Heckelsmiller K; Wei J; Bauernfeind F; Ellermeier J; Kisser U; Bauer CA; Dauer M; Eigler A; Maraskovsky E; Endres S; Schnurr M
Int J Cancer; 2011 Feb; 128(4):897-907. PubMed ID: 20473889
[TBL] [Abstract][Full Text] [Related]
14. Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients.
Winckelmann AA; Munk-Petersen LV; Rasmussen TA; Melchjorsen J; Hjelholt TJ; Montefiori D; Østergaard L; Søgaard OS; Tolstrup M
PLoS One; 2013; 8(4):e62074. PubMed ID: 23637967
[TBL] [Abstract][Full Text] [Related]
15. Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4
Gallotta M; Assi H; Degagné É; Kannan SK; Coffman RL; Guiducci C
Cancer Res; 2018 Sep; 78(17):4943-4956. PubMed ID: 29945961
[TBL] [Abstract][Full Text] [Related]
16. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
17. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
Jordan M; Waxman DJ
Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
[TBL] [Abstract][Full Text] [Related]
18. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors.
El Andaloussi A; Sonabend AM; Han Y; Lesniak MS
Glia; 2006 Nov; 54(6):526-35. PubMed ID: 16906541
[TBL] [Abstract][Full Text] [Related]
20. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine.
den Brok MH; Sutmuller RP; Nierkens S; Bennink EJ; Toonen LW; Figdor CG; Ruers TJ; Adema GJ
Cancer Res; 2006 Jul; 66(14):7285-92. PubMed ID: 16849578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
